MX2023003583A - Forma cristalina del compuesto de piridinilfenilo y metodo de preparacion del mismo. - Google Patents

Forma cristalina del compuesto de piridinilfenilo y metodo de preparacion del mismo.

Info

Publication number
MX2023003583A
MX2023003583A MX2023003583A MX2023003583A MX2023003583A MX 2023003583 A MX2023003583 A MX 2023003583A MX 2023003583 A MX2023003583 A MX 2023003583A MX 2023003583 A MX2023003583 A MX 2023003583A MX 2023003583 A MX2023003583 A MX 2023003583A
Authority
MX
Mexico
Prior art keywords
preparation
crystal form
pyridinylphenyl
compound
method therefor
Prior art date
Application number
MX2023003583A
Other languages
English (en)
Inventor
Xiaolin Li
Haiying He
Peng Li
Shuhui Chen
Guoping Hu
Jian Li
Zhi Luo
Original Assignee
Zhuhai United Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai United Laboratories Co Ltd filed Critical Zhuhai United Laboratories Co Ltd
Publication of MX2023003583A publication Critical patent/MX2023003583A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una forma cristalina de un compuesto de piridinilfenilo y un método de preparación para el mismo; también está comprendido el uso de la forma cristalina en la preparación de un medicamento para tratar las enfermedades relacionadas. (ver Fórmula).
MX2023003583A 2020-09-28 2021-09-28 Forma cristalina del compuesto de piridinilfenilo y metodo de preparacion del mismo. MX2023003583A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011044638 2020-09-28
PCT/CN2021/121466 WO2022063325A1 (zh) 2020-09-28 2021-09-28 吡啶苯基类化合物的晶型及其制备方法

Publications (1)

Publication Number Publication Date
MX2023003583A true MX2023003583A (es) 2023-04-04

Family

ID=80845967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003583A MX2023003583A (es) 2020-09-28 2021-09-28 Forma cristalina del compuesto de piridinilfenilo y metodo de preparacion del mismo.

Country Status (9)

Country Link
US (1) US20230365503A1 (es)
EP (1) EP4219451A1 (es)
JP (1) JP2023543069A (es)
KR (1) KR20230074530A (es)
CN (1) CN116406263A (es)
AU (1) AU2021348707B2 (es)
CA (1) CA3194065A1 (es)
MX (1) MX2023003583A (es)
WO (1) WO2022063325A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6959650B2 (ja) * 2015-08-21 2021-11-02 アルデイラ セラピューティクス， インコーポレイテッド アルデヒドコンジュゲートおよびその使用
EP3694500A4 (en) * 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
WO2020125659A1 (zh) * 2018-12-18 2020-06-25 南京明德新药研发有限公司 用于视网膜疾病的化合物

Also Published As

Publication number Publication date
AU2021348707B2 (en) 2024-04-04
AU2021348707A1 (en) 2023-06-01
JP2023543069A (ja) 2023-10-12
US20230365503A1 (en) 2023-11-16
CN116406263A (zh) 2023-07-07
CA3194065A1 (en) 2022-03-31
WO2022063325A1 (zh) 2022-03-31
KR20230074530A (ko) 2023-05-30
EP4219451A1 (en) 2023-08-02
AU2021348707A9 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2023006854A (es) Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
WO2023081830A3 (en) Compositions and treatments with nirogacestat
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
MX2021003127A (es) Uso de un inhibidor de catepsina s contra la formacion de anticuerpos antifarmaco.
WO2020132560A3 (en) Compositions and methods for cancer therapy
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
WO2020128614A8 (en) Method for treating interstital lung disease
AU2021348707A9 (en) Crystal form of pyridinylphenyl compound and preparation method therefor
MX2021009170A (es) Cristal de compuesto de diariltiohidantoina.
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
WO2019173478A3 (en) Combination of depletes tregs and a checkpoint inhibitor
MX2021016043A (es) Formulacion de doxorrubicina liposomal, metodo para producir una formulacion de doxorrubicina liposomal y uso de una formulacion de doxorrubicina liposomal como un medicamento.
EA202193211A1 (ru) Лечение синуклеопатий
AU2020327022A8 (en) Method of treating cancer
WO2023240199A3 (en) Fitusiran for the treatment of hemophilia a and b
EP4257128A3 (en) Methods and compounds for the treatment of genetic disease
MX2022007071A (es) Uso de un inhibidor de pcsk9 para tratar la hipercolesterolemia familiar homocigotica.